Discovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors
Özet
Sulfonamides are among the most promising potential inhibitors for carbonic anhydrases (CAs), which are pharmaceutically relevant targets for treating several disease conditions. Herein, a series of benzenesulfonamides bearing 1,2,3-triazole moiety as inhibitors of human (h) α-CAs (hCAs) were designed using the tail approach. The design method combines a benzenesulfonamide moiety with a tail of oxime and a zinc-binding group on a 1,2,3-triazole scaffold. Among the synthesized derivatives, the naphthyl (6m, KI of 68.6 nM, SI of 10.3), and methyl (6a, KI of 56.3 nM, SI of 11.7) derivatives (over hCA IX) and propyl (6c, KI of 95.6 nM, SI of 2.7), and pentyl (6d, KI of 51.1 nM, SI of 6.6) derivatives (over hCA XII) displayed a noticeable selectivity for isoforms hCA I and II, respectively. Meanwhile, derivative 6e displayed a potent inhibitory effect versus the cytosolic isoform hCA I (KI of 47.8 nM) and tumor-associated isoforms hCA IX and XII (KIs of 195.9 and 116.9 nM, respectively) compared with the reference drug acetazolamide (AAZ, KIs of 451.8, 437.2, and 338.9 nM, respectively). Derivative 6b showed higher potency (KI of 33.2 nM) than AAZ (KI of 327.3 nM) towards another cytosolic isoform hCA II. Nevertheless, substituting the lipophilic large naphthyl tail to the 1,2,3-triazole linked benzenesulfonamides (6a-n) raised inhibitory effect versus hCA I and XII and selectivity towards hCA I and II isoforms over hCA IX. Evaluation of the cytotoxic potential of the synthesized derivatives was conducted in L929, MCF-7, and Hep-3B cell lines. Several compounds in the series demonstrated significant antiproliferative activity and minimal cytotoxicity. In the molecular docking study, the sulfonamide moiety interacted with the zinc-ion and neatly fit into the hCAs active sites. The extension of the tail was found to participate in diverse hydrophilic and hydrophobic interactions with adjacent amino acids, ultimately influencing the effectiveness and specificity of the derivatives. © 2023 Elsevier B.V.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Buza, Aida | |
| dc.contributor.author | Türkeş, Cüneyt | |
| dc.contributor.author | Arslan, Mustafa | |
| dc.contributor.author | Demir, Yeliz | |
| dc.contributor.author | Dincer, Busra | |
| dc.contributor.author | Nixha, Arleta Rifati | |
| dc.contributor.author | Beydemir, Sükrü | |
| dc.date.accessioned | 2026-10-18T20:27:04.650601103Z | |
| dc.date.available | 2026-10-18T20:27:04.650601103Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Sulfonamides are among the most promising potential inhibitors for carbonic anhydrases (CAs), which are pharmaceutically relevant targets for treating several disease conditions. Herein, a series of benzenesulfonamides bearing 1,2,3-triazole moiety as inhibitors of human (h) α-CAs (hCAs) were designed using the tail approach. The design method combines a benzenesulfonamide moiety with a tail of oxime and a zinc-binding group on a 1,2,3-triazole scaffold. Among the synthesized derivatives, the naphthyl (6m, KI of 68.6 nM, SI of 10.3), and methyl (6a, KI of 56.3 nM, SI of 11.7) derivatives (over hCA IX) and propyl (6c, KI of 95.6 nM, SI of 2.7), and pentyl (6d, KI of 51.1 nM, SI of 6.6) derivatives (over hCA XII) displayed a noticeable selectivity for isoforms hCA I and II, respectively. Meanwhile, derivative 6e displayed a potent inhibitory effect versus the cytosolic isoform hCA I (KI of 47.8 nM) and tumor-associated isoforms hCA IX and XII (KIs of 195.9 and 116.9 nM, respectively) compared with the reference drug acetazolamide (AAZ, KIs of 451.8, 437.2, and 338.9 nM, respectively). Derivative 6b showed higher potency (KI of 33.2 nM) than AAZ (KI of 327.3 nM) towards another cytosolic isoform hCA II. Nevertheless, substituting the lipophilic large naphthyl tail to the 1,2,3-triazole linked benzenesulfonamides (6a-n) raised inhibitory effect versus hCA I and XII and selectivity towards hCA I and II isoforms over hCA IX. Evaluation of the cytotoxic potential of the synthesized derivatives was conducted in L929, MCF-7, and Hep-3B cell lines. Several compounds in the series demonstrated significant antiproliferative activity and minimal cytotoxicity. In the molecular docking study, the sulfonamide moiety interacted with the zinc-ion and neatly fit into the hCAs active sites. The extension of the tail was found to participate in diverse hydrophilic and hydrophobic interactions with adjacent amino acids, ultimately influencing the effectiveness and specificity of the derivatives. © 2023 Elsevier B.V. | |
| dc.description.sponsorship | This work was supported by the Research Fund of Sakarya University (grant number 2020-9-32-85 ), the Research Fund of Erzincan Binali Yıldırım University (grant number TSA-2020-729 ), and the Research Fund of Anadolu University (grant number 2102S003 ). | |
| dc.identifier.doi | 10.1016/j.ijbiomac.2023.124232 | |
| dc.identifier.eissn | 1879-0003 | |
| dc.identifier.issn | 0141-8130 | |
| dc.identifier.pmid | 37001773 | |
| dc.identifier.scopus | 2-s2.0-85151430516 | |
| dc.identifier.startpage | 124232 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12133 | |
| dc.identifier.volume | 239 | |
| dc.identifier.wos | WOS:000970836600001 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | International Journal of Biological Macromolecules | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Benzenesulfonamide | |
| dc.subject | Carbonic anhydrase | |
| dc.subject | Cytotoxicity | |
| dc.subject | In silico study | |
| dc.subject | Selective inhibitor | |
| dc.subject | Amines | |
| dc.subject | Carbonic Anhydrase I | |
| dc.subject | Carbonic Anhydrase Inhibitors | |
| dc.subject | Carbonic Anhydrase IX | |
| dc.subject | Carbonic Anhydrases | |
| dc.subject | Humans | |
| dc.subject | Molecular Docking Simulation | |
| dc.subject | Molecular Structure | |
| dc.subject | Protein Isoforms | |
| dc.subject | Structure-Activity Relationship | |
| dc.subject | Sulfonamides | |
| dc.subject | Triazoles | |
| dc.subject | 1,2,3 triazole derivative | |
| dc.subject | 2 [({1 [5 methyl 1 (4 sulfamoylphenyl) 1H 1,2,3 triazol 4 yl] ethylidene}amino)oxy]acetamide | |
| dc.subject | 4 (4 1 [(heptyloxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl)benzenesulfonamide | |
| dc.subject | 4 (4 {1 [(Allyloxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl) benzenesulfonamide | |
| dc.subject | 4 (4 {1 [(anthracen 9 ylmethoxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl)benzenesulfonamide | |
| dc.subject | 4 (4 {1 [(but 3 en 1 yloxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl)benzenesulfonamide | |
| dc.subject | 4 (5 methyl 4 {1 [(naphthalen 1 ylmethoxy)imino]ethyl} 1H 1,2,3 triazol 1 yl)benzenesulfonamide | |
| dc.subject | 4 (5 methyl 4 {1 [(octyloxy)imino]ethyl} 1H 1,2,3 triazol 1 yl) benzenesulfonamide | |
| dc.subject | 4 (5 methyl 4 {1 [(pentyloxy)imino]ethyl} 1H 1,2,3 triazol 1 yl)benzenesulfonamide | |
| dc.subject | 4 (5 methyl 4 {1 [(prop 2 yn 1 yloxy)imino]ethyl} 1H 1,2,3 triazol 1 yl)benzenesulfonamide | |
| dc.subject | 4 {4 [1 (methoxyimino)ethyl] 5 methyl 1H 1,2,3 triazol 1 yl} benzenesulfonamide | |
| dc.subject | 4 {5 methyl 4 [1 (propoxyimino)ethyl] 1H 1,2,3 triazol 1 yl} benzenesulfonamide | |
| dc.subject | 4{4 [1 (ethoxyimino)ethyl] 5 methyl 1H 1,2,3 triazol 1 yl}benzenesulfonamide | |
| dc.title | Discovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 83 | |
| rdl.citation.wos | 78 | |
| rdl.department | Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey. Electronic address: cuneyt.turkes@erzincan.edu.tr. | Department of Pharmacology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey. | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
